Rapamycin binds to FKBP12 and inhibits mechanistic target of rapamycin complex 1 (mTORC1), a central nutrient-sensing kinase that coordinates anabolic and catabolic processes. This inhibition suppresses mTORC1-driven protein synthesis and activates autophagy, thereby modulating the nutrient-sensing aging pathway identified as a conserved regulator of lifespan across model organisms. In preclinical models, chronic rapamycin administration extends lifespan in mice, yeast, and C. elegans; human data remain limited to surrogate biomarkers showing improvements in immune function, cardiometabolic parameters, and reduced cancer incidence in transplant cohorts, though direct effects on human healthspan or lifespan remain unproven. Current evidence supports mTORC1 inhibition as a plausible aging-pathway intervention, but the therapeutic window, optimal dosing strategies, and long-term safety profile in non-immunosuppressed populations require further investigation.
No. Rapamycin (sirolimus) is FDA-approved for preventing organ transplant rejection and for seizures associated with Tuberous Sclerosis Complex. Its use for longevity or healthspan purposes is off-label and not an FDA-recognized indication.
Geroevidence tracks ongoing human trials studying rapamycin in longevity contexts, including the PEARL trial (immune function outcomes). Current evidence is graded Moderate — see the full profile for trial-level detail and indexed papers.
Geroevidence's four-tier system is an internal editorial classification, not a regulatory determination or clinical practice guideline. It reflects the volume and quality of published evidence available at time of review.
Published data, primarily from transplant medicine, identifies infection risk, mouth ulcers (stomatitis), and lipid changes as commonly reported effects. Long-term safety data specific to low-dose, intermittent dosing protocols studied for longevity in healthy adults remains more limited than safety data in the approved transplant indication.
Both are currently graded Moderate on Geroevidence, but rapamycin's evidence is built primarily on mechanistic and surrogate-endpoint data, while metformin has a pooled mortality hazard ratio from meta-analytic data. See the metformin profile for direct comparison.